Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib

Tumor Progression and Oncogene Addiction in a PDGF-B-Induced Model of Gliomagenesis

(2015) Filippo Calzolari et al.   NEOPLASIA

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

(2010) A. F. Leary et al.   CLINICAL CANCER RESEARCH

ERBB1 and ERBB2 Have Distinct Functions in Tumor Cell Invasion and Intravasation

(2009) D. Kedrin et al.   CLINICAL CANCER RESEARCH

The mammalian anti-proliferative BTG/Tob protein family

(2009) G. Sebastiaan Winkler   JOURNAL OF CELLULAR PHYSIOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology

HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis

(2009) T. Hayashida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BTG/TOB factors impact deadenylases

(2009) Fabienne Mauxion et al.   TRENDS IN BIOCHEMICAL SCIENCES

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

(2008) Sherene Loi et al.   BMC GENOMICS

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

(2008) P K Julka et al.   BRITISH JOURNAL OF CANCER

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

(2008) G E Konecny et al.   BRITISH JOURNAL OF CANCER

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CANCER RESEARCH

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers

(2008) Michèle Sabbah et al.   DRUG RESISTANCE UPDATES

The BTG2 protein is a general activator of mRNA deadenylation

(2008) Fabienne Mauxion et al.   EMBO JOURNAL

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

(2008) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain

(2008) B. Gril et al.   JNCI-Journal of the National Cancer Institute

Stromal gene expression predicts clinical outcome in breast cancer

(2008) Greg Finak et al.   NATURE MEDICINE